Bionaut Pharmaceuticals Continues to Build Management Team; Company to Present March 15th at the S.G. Cowen & Co. 25th Annual Healthcare Conference.CAMBRIDGE, Mass. -- Bionaut Pharmaceuticals today announced the appointments of Gregory Gardiner Ph.D., former Group Director of R&D Operations, Pfizer Central Research and Director of Bionaut, to Chief Executive Officer and John M. Sorvillo, Ph.D., formerly Vice President of ArQule, to Chief Business Officer. "Greg's and John's wealth of experience in research and drug development as well as in establishing corporate collaborations in the biotechnology and pharmaceutical industry is impressive," states Timothy F. Howe, Bionaut director and partner with lead investor CHL CHL crown-heel length. Medical Partners. "Their skills are particularly important to our strategy at this time since we now have several programs nearing the partnering stage in cancer, macular degeneration macular degeneration, eye disorder causing loss of central vision. The affected area, the macula, lies at the back of the retina and is the part that produces the sharpest vision. and inflammation, in addition to our other programs in early development." Gregory Gardiner, Ph.D. was former Group Director of R&D Operations, Pfizer Central Research, where he designed and implemented Pfizer's external biotechnology strategy. Dr. Gardiner also participated in the management of Pfizer's worldwide drug discovery program, and was responsible for the scientific evaluation of licensing candidates including Lipitor, Celebrex, and Aricept. He currently serves as an advisor to Yale University's Office of Cooperative Research (OCR OCR in full optical character recognition Scanning and comparison technique intended to identify printed text or numerical data. It avoids the need to retype already printed material for data entry. ), a director of four biotech companies and a consultant and advisor to several investment funds Noun 1. investment funds - money that is invested with an expectation of profit investment assets - anything of material value or usefulness that is owned by a person or company and pharmaceutical and biotech companies. John Sorvillo, Ph.D. served for nine years as Vice President of Business Development at ArQule, a Boston-based biotechnology company engaged in the research and development of small-molecule cancer therapeutics. During his time at ArQule, John was responsible for establishing many of ArQule's collaborations with major pharmaceutical companies. Prior to joining ArQule, for ten years, Dr. Sorvillo held a variety of scientific and business positions at OSI Pharmaceuticals OSI Pharmaceuticals, Inc. is an American pharmaceutical company based in Long Island, New York with facilities in Colorado, New Jersey and the United Kingdom. They specialize in the discovery and development of molecular targeted therapies, and are listed in the NASDAQ , Inc. (Oncogene oncogene Gene that can cause cancer. It is a sequence of DNA that has been altered or mutated from its original form, the proto-oncogene (see mutation). Proto-oncogenes promote the specialization and division of normal cells. Science, Inc.) including his last position as Vice President and General Manager. Dr. Sorvillo attended the Massachusetts Institute of Technology Massachusetts Institute of Technology, at Cambridge; coeducational; chartered 1861, opened 1865 in Boston, moved 1916. It has long been recognized as an outstanding technological institute and its Sloan School of Management has notable programs in business, Sloan School Program for Senior Executives. He was a postdoctoral fellow at Memorial Sloan Kettering Cancer Center, received his Ph.D. in Immunology from the New York University New York University, mainly in New York City; coeducational; chartered 1831, opened 1832 as the Univ. of the City of New York, renamed 1896. It comprises 13 schools and colleges, maintaining 4 main centers (including the Medical Center) in the city, as well as the Medical Center and his B.A. in Biology from the City University of New York The City University of New York (CUNY; acronym: IPA pronunciation: [kjuni]), is the public university system of New York City. , Hunter College. "John's demonstrated success in establishing high-value business development deals at both ArQule and OSI (1) (Open System Interconnection) An ISO standard for worldwide communications that defines a framework for implementing protocols in seven layers. Control is passed from one layer to the next, starting at the application layer in one station, proceeding to the will be a tremendous asset for Bionaut as we embark on partnerships for our lead programs," stated Gregory Gardiner, Ph.D, Director and Chief Executive Officer of Bionaut. Bionaut Pharmaceuticals will be presenting at the S.G. Cowen & Co. 25th Annual Healthcare Conference at 3:30 PM on March 15th at the Marriott Copley Place in Boston. About Bionaut Pharmaceuticals Bionaut's business strategy is to discover novel small molecule drug candidates that affect well-validated disease pathways and to advance such discoveries through late stage pre-clinical status for further development in partnership with pharmaceutical and large biotechnology companies. Bionaut employs its patented Sentinel Pathway Reporter System(TM) to initiate the discovery process. Bionaut's Sentinel system can greatly increase the chances of a positive clinical outcome for a new drug candidate by correlating pathway-specific interference directly with disease modulation in living human cells. Bionaut has applied the highly predictive capabilities of its Sentinel system to build a pipeline of its own drug candidates in the areas of cancer and inflammation and continues to expand its efforts to other therapeutic areas. In addition, Bionaut will assist strategic partners with drug discovery and lead optimization in disease areas of their choice. More information about Bionaut can be found on the Company's website at www.bionautpharma.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion